Literature DB >> 9014669

Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin.

D Bergqvist1, B Lindgren, T Mätzsch.   

Abstract

The relative costs were analysed of (1) no prophylaxis against deep vein thrombosis (DVT), (2) selective treatment of DVT after confirmation of diagnosis, (3) general prophylaxis with standard low-dose unfractionated heparin and (4) general prophylaxis with low molecular weight heparin (LMWH) in patients undergoing elective general abdominal surgery or elective hip surgery. The mean calculated costs per patient undergoing general abdominal surgery were: Swedish crowns (SEK) 1950 for no prophylaxis, SEK 5710 for selective treatment of DVT, SEK 735 for prophylaxis with unfractionated heparin and SEK 665 for prophylaxis with LMWH. The corresponding costs for hip surgery were SEK 3930, SEK 10790, SEK 1730 and SEK 1390 respectively. Thus, the least expensive management strategy in patients undergoing elective general abdominal or hip surgery would appear to be general prophylaxis with either unfractionated heparin or LMWH. Furthermore, general prophylaxis with LMWH would appear to be more cost-effective than general prophylaxis with unfractionated heparin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9014669     DOI: 10.1002/bjs.1800831117

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  7 in total

Review 1.  Formulary management of low molecular weight heparins.

Authors:  W E Wade; B C Martin; J A Kotzan; W J Spruill; M A Chisoholm; M Perri
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

Review 2.  Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  R Davis; D Faulds
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

3.  Management and prevention of venous thromboembolism including surgery and the pregnant state.

Authors:  Steven B Deitelzweig
Journal:  Ochsner J       Date:  2002

4.  Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes.

Authors:  David Bergqvist
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 5.  Venous thromboembolism in Pakistan: a neglected research agenda.

Authors:  Abdul Ahad Khan; Syed Nabeel Zafar
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

6.  Hospital-based costs associated with venous thromboembolism prophylaxis regimens.

Authors:  Geno Merli; Cheryl P Ferrufino; Jay Lin; Mohammed Hussein; David Battleman
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

7.  An economic evaluation of the costs and benefits of heparin rationalisation in a hospital pharmacy.

Authors:  Penny Reeves; Jonathan Cooke; Adam Lloyd; Adam Hutchings
Journal:  Pharm World Sci       Date:  2004-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.